SAB BIOTHERAPEUTICS INC (SABS) competitors & alternatives
Health Care · NASDAQ
SAB BIOTHERAPEUTICS INC (SABS)'s top competitors and alternatives — its most similar public companies — include Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Cue Biopharma, Inc. (CUE), TRISALUS LF SC CM A (TLSI), ACUMEN PHARMACEUTICALS INC (ABOS), ARTIVA BIOTHERAPEUTICS INC (ARTV), CONTEXT THERAPEUTICS INC (CNTX), REPLIMUNE GROUP INC (REPL), JANUX THERAPEUTICS INC (JANX), BICARA THERAPEUTICS INC (BCAX), SELLAS LIFE SCIENCES GROUP INC (SLS) and CG ONCOLOGY INC (CGON). These are SAB BIOTHERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top SABS competitors & alternatives
-
Regeneron PharmaceuticalsREGNHealth Care
Regeneron develops and commercializes monoclonal antibody and other biologics therapies across immunology, oncology, infectious disease, and other therapeutic…
$651.91 (as of 2026-07-23) · market cap $67.4B
-
Vertex PharmaceuticalsVRTXHealth Care
Vertex Pharmaceuticals develops transformative medicines for serious genetic diseases, with a dominant pipeline anchored in cystic fibrosis treatments and…
$473.09 (as of 2026-07-23) · market cap $119.3B
-
Cue Biopharma, Inc.CUEHealth Care
Cue Biopharma engineers injectable biologics that selectively modulate disease-specific T cells to restore immune tolerance in autoimmune diseases and activate…
$33.09 (as of 2026-07-23) · market cap $138M
-
TRISALUS LF SC CM ATLSIHealth Care
TriSalus is a medical technology company integrating proprietary pressure-enabled drug delivery devices with immunotherapeutics to improve outcomes for…
$4.27 (as of 2026-07-23) · market cap $260M
-
ACUMEN PHARMACEUTICALS INCABOSHealth Care
Clinical-stage biotech developing sabirnetug, a monoclonal antibody that targets amyloid-beta oligomers to modify disease progression in Alzheimer's patients,…
$2.17 (as of 2026-07-23) · market cap $160M
-
ARTIVA BIOTHERAPEUTICS INCARTVHealth Care
Artiva Biotherapeutics develops allogeneic natural killer cell immunotherapies for cancer, with its lead candidate AlloNK advancing through clinical trials.
$10.13 (as of 2026-07-23) · market cap $487M
-
CONTEXT THERAPEUTICS INCCNTXHealth Care
Clinical-stage biopharmaceutical company developing T-cell engaging bispecific antibodies to treat solid tumors by redirecting immune cells against cancer…
$0.59 (as of 2026-07-23) · market cap $56M
-
REPLIMUNE GROUP INCREPLHealth Care
Replimune is developing engineered oncolytic viruses that directly kill tumors while triggering systemic anti-tumor immunity, with its lead candidate RP1 in…
$10.46 (as of 2026-07-23) · market cap $879M
-
JANUX THERAPEUTICS INCJANXHealth Care
Janux Therapeutics is a clinical-stage biotech developing next-generation, tumor-activated bispecific immunotherapies to improve the safety and efficacy of…
$15.72 (as of 2026-07-23) · market cap $953M
-
BICARA THERAPEUTICS INCBCAXHealth Care
Bicara Therapeutics is developing a pipeline of bifunctional antibodies that precisely target and neutralize both EGFR and TGF-β pathways to improve treatment…
$27.73 (as of 2026-07-23) · market cap $1.8B
-
SELLAS LIFE SCIENCES GROUP INCSLSHealth Care
SELLAS Life Sciences is a clinical-stage biotech developing targeted immunotherapies and small molecule inhibitors to treat a variety of hematologic and solid…
$12.34 (as of 2026-07-23) · market cap $2.3B
-
CG ONCOLOGY INCCGONHealth Care
An early-stage immuno-oncology company developing cretostimogene, a novel therapeutic candidate for high-risk and intermediate-risk non-muscle-invasive bladder…
$71.12 (as of 2026-07-23) · market cap $6.1B
Not quite? Describe exactly what you want →
Peers are SAB BIOTHERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: SAB BIOTHERAPEUTICS INC (SABS).
Last updated 2026-07-23.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.